-
公开(公告)号：US10800845B2
公开(公告)日：2020-10-13
申请号：US16402829
申请日：2019-05-03
发明人： Leonie Alten , Dominik Maurer , Steffen Walter , Sebastian Bunk
摘要： The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
-
公开(公告)号：US10793602B2
公开(公告)日：2020-10-06
申请号：US16582957
申请日：2019-09-25
发明人： Toni Weinschenk , Steffen Walter , Jens Fritsche , Colette Song , Harpreet Singh
摘要： A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
公开(公告)号：US10526407B2
公开(公告)日：2020-01-07
申请号：US16035300
申请日：2018-07-13
发明人： Leonie Alten , Dominik Maurer , Steffen Walter , Sebastian Bunk
摘要： The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
-
公开(公告)号：US10478471B2
公开(公告)日：2019-11-19
申请号：US16502268
申请日：2019-07-03
摘要： A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
公开(公告)号：US10160786B1
公开(公告)日：2018-12-25
申请号：US16100858
申请日：2018-08-10
发明人： Toni Weinschenk , Steffen Walter , Jens Fritsche , Colette Song , Harpreet Singh
摘要： A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
56.发明申请公开(公告)号：US20170304399A1
公开(公告)日：2017-10-26
申请号：US15636486
申请日：2017-06-28
摘要： A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
公开(公告)号：US09308244B2
公开(公告)日：2016-04-12
申请号：US14453410
申请日：2014-08-06
发明人： Harpreet Singh , Niels Emmerich , Nobert Hilf , Steffen Walter , Toni Weinschenk
IPC分类号： A61K39/00 , A61K31/404
CPC分类号： A61K39/0011 , A61K31/404 , A61K2039/54 , A61K2039/545 , A61K2039/55505 , A61K2039/55561
摘要： The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or class-II. Preferably the multi-kinase inhibitor is sunitinib malate and/or sorafenib tosylate or a pharmaceutically acceptable salt thereof.
摘要翻译： 本发明涉及在哺乳动物中治疗癌症的方法，包括向哺乳动物施用包含疫苗和多激酶抑制剂的组合疗法，其中所述疫苗包含具有结合人类分子的能力的分离的肿瘤相关肽 主要组织相容性复合体（MHC）I类或II类。 优选地，多激酶抑制剂是苹果酸舒尼替尼和/或甲苯磺酸索拉菲尼或其药学上可接受的盐。
-
公开(公告)号：US11986497B2
公开(公告)日：2024-05-21
申请号：US18166936
申请日：2023-02-09
发明人： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC分类号： C07K7/06 , A61K35/17 , A61K39/00 , C07K7/08 , C07K14/47 , C07K14/495 , C07K14/725 , C07K16/40 , C07K19/00 , C12N5/0783 , C12N9/02 , C12N9/10 , A61K38/00
CPC分类号： A61K35/17 , A61K39/0011 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K2317/34 , C07K2319/00 , C12N2502/1157 , C12Y208/02011
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US11957730B2
公开(公告)日：2024-04-16
申请号：US17383855
申请日：2021-07-23
CPC分类号： A61K38/1709 , A61K39/0011 , A61P35/00 , C07K7/06 , G01N33/505 , A61K2039/5158 , A61K2039/572 , A61K2039/585 , C07K2319/00
摘要： A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
公开(公告)号：US11890334B2
公开(公告)日：2024-02-06
申请号：US17390584
申请日：2021-07-30
发明人： Sabrina Kuttruff-Coqui , Toni Weinschenk , Jens Fritsche , Steffen Walter , Norbert Hilf , Oliver Schoor , Colette Song , Harpreet Singh
IPC分类号： C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , A61P35/02 , A61P35/00 , A61K35/17 , A61K39/00 , C12N5/0783 , C07K14/705 , C07K7/06 , C07K7/08 , C12Q1/6886
CPC分类号： A61K39/0011 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/4748 , C07K14/705 , C07K14/70539 , C07K16/2833 , C12Q1/6886 , A61K2039/5158 , A61K2039/572 , A61K2039/80 , C07K2319/33 , C12Q2600/136 , C12Q2600/158 , C12Q2600/16
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
-
-
-
-
-
-
-
-
搜索结果
74 条记录 (耗时 0.036 秒)
